LifeScience Cell & Gene

Artiva Biotherapeutics Initiates First U.S. Trial of Allogeneic NK Cell Therapy for Lupus Nephritis

Artiva Biotherapeutics, Inc., a clinical-stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-bas...

 April 18, 2024 | News

SCG Cell Therapy and A*STAR Launch Joint Labs to Advance Cellular Immunotherapy in Singapore

Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates to facilitate research leading to translation of...

 April 18, 2024 | News

CSafe Launches Cryogenic Dewars for Cell and Gene Therapies

CSafe, an active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, proudly announces the launch of a new l...

 April 17, 2024 | News

IASO Bio's BCMA CAR-T Therapy Eque-cel Receives FDA Approval for U.S. Clinical Trials in Myasthenia Gravis

 IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell ...

 April 08, 2024 | News

YolTech Therapeutics Initiates Clinical Trial for Gene Editing Treatment YOLT-101 Targeting Familial Hypercholesterolemia

YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company's in vivo genome editing candidate being develope...

 April 03, 2024 | News

IASO Bio Gains NMPA Approval for Multiple Myeloma Treatment IND

IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, anno...

 April 01, 2024 | News

EditCo Bio Launches with Acquisition of Synthego's Cell Engineering Divisions to Boost CRISPR Market Innovations

EditCo Bio, Inc. announced that it has launched its business with the acquisition of Synthego's engineered cell solutions and enhanced guide RNA business. ...

 March 28, 2024 | News

Integrated DNA Technologies Launches Innovative Custom Vector Onboarding Tool to Streamline Gene Synthesis

Integrated DNA Technologies (IDT), a global leader in genomics solutions, announced  the expansion of its gene synthesis services with the launch of a...

 March 28, 2024 | News

Nanoscope Therapeutics Achieves Breakthrough in Retinitis Pigmentosa Treatment with MCO-010 Gene Therapy

Nanoscope Therapeutics, a pioneering biotechnology firm, unveiled groundbreaking results from the Phase 2b RESTORE trial of MCO-010...

 March 27, 2024 | News

Andelyn Biosciences and Grace Science Partner on Gene Therapy for Rare Disease

 Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has par...

 March 26, 2024 | News

NeuExcell Therapeutics Launches Pioneering Gene Therapy Trial for Glioblastoma Patients

NeuExcell Therapeutics, a leading biotechnology company focused on in vivo neural regenerative therapies, announces the successful dosing of the ...

 March 22, 2024 | News

European Commission Approves Bristol Myers Squibb’s Abecma as First Earlier-Line CAR T Therapy for Multiple Myeloma"

Bristol Myers Squibb announced a significant advancement in the treatment of multiple myeloma with the European Commission's approval of Abecma® (ideca...

 March 21, 2024 | News

FDA Greenlights Lenmeldy, First Gene Therapy for Devastating Genetic Disorder Metachromatic Leukodystrophy

Metachromatic leukodystrophy is a debilitating, rare genetic disease affecting the brain and nervous system. It is caused by a deficiency of an enzyme call...

 March 19, 2024 | News

Bristol Myers Squibb’s Breyanzi Approved as First CAR T Cell Therapy for CLL/SLL

  Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients wit...

 March 15, 2024 | News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in